Why did IMMX's EPS remain stagnant in recent quarters?

The EPS of Immix Biopharma (IMMX) has not remained stagnant; it has actually shown an improvement in the recent past. Let's break down the key points to understand the trend in IMMX's EPS:

1. **Improvement in EPS**: The EPS for IMMX has shown a positive trend, with the most recent report period ending on December 31, 2024, showing a diluted EPS of -$0.15. This is an improvement from the previous quarter's EPS of -$0.24.

|code|Ticker|Name|Date|Net Income YoY|Total Revenue YoY|Diluted EPS YoY|market_code|
|---|---|---|---|---|---|---|---|
|IMMX|IMMX.O|Immix Biopharma|2024 Q1|-113.41055679030534||-22.222222222222225|186|
|IMMX|IMMX.O|Immix Biopharma|2024 Q2|-22.445536838852185||37.5|186|
|IMMX|IMMX.O|Immix Biopharma|2024 Q3|-64.58425032551304||-4.3478260869565135|186|
|IMMX|IMMX.O|Immix Biopharma|2024 Q4|6.659313810115519|||186|

2. **Stock Repurchases Impact**: The company's stock repurchases have led to a reduction in share count, which has positively impacted the diluted EPS. This reduction in share count offsets the lower net income, resulting in a stable or improving EPS.
3. **Strategic Focus**: IMMX has been focusing on investing in and expanding its high-margin digital business while leveraging the strength of its underlying retail model. This strategic focus suggests a potential for improved profitability and could be a contributing factor to the stable or improving EPS.

In conclusion, IMMX's EPS has not remained stagnant; it has shown an improving trend due to various factors such as stock repurchases and strategic focus.